Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)
This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2020-08, Vol.123 (4), p.510-517 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 517 |
|---|---|
| container_issue | 4 |
| container_start_page | 510 |
| container_title | British journal of cancer |
| container_volume | 123 |
| creator | Kyrgiou, Maria Arbyn, Marc Bergeron, Christine Bosch, F. Xavier Dillner, Joakim Jit, Mark Kim, Jane Poljak, Mario Nieminen, Pekka Sasieni, Peter Kesic, Vesna Cuzick, Jack Gultekin, Murat |
| description | This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising. |
| doi_str_mv | 10.1038/s41416-020-0920-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_470692</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475015087</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-854ed73981a7a02c3a94f5fbd9a947d2df49114d1bb909ba3df02d46b03c4fbc3</originalsourceid><addsrcrecordid>eNp9ks1uEzEUhUcIRNPCA7BBlti0iwH_TTxmUQmNkhSpUhaFteWx76RTJvZgT4ryHLwwniRtCVLZ2Ne-3zn-0cmydwR_JJiVnyInnExzTHGOZRrki2xCCkZzUlLxMptgjMWuc5KdxniXlhKX4nV2wmiBRVkUk-x3BeG-NbpD0QQA17rVZzS7WSzz2bxCvY_t0HqHet1DQL5Bwy2g2Sb4HrRDN960MGzH_cXWaTC-86vWoKXbVVt0PjpdIO3ssXAOFoLeOSdt5bt0kPH9KJhXF2-yV43uIrw9zGfZ9_nsW3WVXy8XX6sv17kpyumQlwUHK5gsiRYaU8O05E3R1FamQlhqGy4J4ZbUtcSy1sw2mFo-rTEzvKkNO8vyvW_8Bf2mVn1o1zpsldetOmz9SBUoLvBU0sTLZ_k-ePskehASzkrJuMRJe7nXJmAN1oAbgu6OLY46rr1VK3-vBGe8FCwZnB8Mgv-5gTiodRsNdJ124DdRUU6wwFIIktAP_6B3fhNc-spEiQKTIqXg_xRLFE1JShTZUyb4GAM0j1cmWI0hVPsQqhRCNUZNyaR5__dbHxUPqUsAPXxkarkVhKejn3f9A5VY6Gs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2435012532</pqid></control><display><type>article</type><title>Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)</title><source>MEDLINE</source><source>SWEPUB Freely available online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kyrgiou, Maria ; Arbyn, Marc ; Bergeron, Christine ; Bosch, F. Xavier ; Dillner, Joakim ; Jit, Mark ; Kim, Jane ; Poljak, Mario ; Nieminen, Pekka ; Sasieni, Peter ; Kesic, Vesna ; Cuzick, Jack ; Gultekin, Murat</creator><creatorcontrib>Kyrgiou, Maria ; Arbyn, Marc ; Bergeron, Christine ; Bosch, F. Xavier ; Dillner, Joakim ; Jit, Mark ; Kim, Jane ; Poljak, Mario ; Nieminen, Pekka ; Sasieni, Peter ; Kesic, Vesna ; Cuzick, Jack ; Gultekin, Murat</creatorcontrib><description>This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising.</description><identifier>ISSN: 0007-0920</identifier><identifier>ISSN: 1532-1827</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-020-0920-9</identifier><identifier>PMID: 32507855</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/700/1538 ; 692/700/459/1748 ; 706/648/160 ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cellular biology ; Cervical cancer ; Cervix Uteri - virology ; Colposcopy ; Consensus ; Consensus Statement ; Cyclin-Dependent Kinase Inhibitor p16 - metabolism ; Cytology ; Drug Resistance ; Early Detection of Cancer ; Epidemiology ; Female ; Genotyping ; Genotyping Techniques ; Humans ; Immunization ; Medical screening ; Medicin och hälsovetenskap ; Methylation ; Molecular Medicine ; Oncology ; Papillomaviridae - genetics ; Papillomaviridae - isolation & purification ; Papillomavirus Infections - diagnosis ; Papillomavirus Infections - metabolism ; Papillomavirus Vaccines - therapeutic use ; Practice Guidelines as Topic ; Pregnancy ; Quality assurance ; Sensitivity and Specificity ; Uterine Cervical Neoplasms - virology ; Vaccination ; Vaccination - statistics & numerical data ; Viral Load</subject><ispartof>British journal of cancer, 2020-08, Vol.123 (4), p.510-517</ispartof><rights>Cancer Research UK 2020</rights><rights>Cancer Research UK 2020.</rights><rights>Cancer Research UK 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-854ed73981a7a02c3a94f5fbd9a947d2df49114d1bb909ba3df02d46b03c4fbc3</citedby><cites>FETCH-LOGICAL-c586t-854ed73981a7a02c3a94f5fbd9a947d2df49114d1bb909ba3df02d46b03c4fbc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434873/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434873/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32507855$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:143893490$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Kyrgiou, Maria</creatorcontrib><creatorcontrib>Arbyn, Marc</creatorcontrib><creatorcontrib>Bergeron, Christine</creatorcontrib><creatorcontrib>Bosch, F. Xavier</creatorcontrib><creatorcontrib>Dillner, Joakim</creatorcontrib><creatorcontrib>Jit, Mark</creatorcontrib><creatorcontrib>Kim, Jane</creatorcontrib><creatorcontrib>Poljak, Mario</creatorcontrib><creatorcontrib>Nieminen, Pekka</creatorcontrib><creatorcontrib>Sasieni, Peter</creatorcontrib><creatorcontrib>Kesic, Vesna</creatorcontrib><creatorcontrib>Cuzick, Jack</creatorcontrib><creatorcontrib>Gultekin, Murat</creatorcontrib><title>Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising.</description><subject>692/700/1538</subject><subject>692/700/459/1748</subject><subject>706/648/160</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Cervix Uteri - virology</subject><subject>Colposcopy</subject><subject>Consensus</subject><subject>Consensus Statement</subject><subject>Cyclin-Dependent Kinase Inhibitor p16 - metabolism</subject><subject>Cytology</subject><subject>Drug Resistance</subject><subject>Early Detection of Cancer</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Genotyping</subject><subject>Genotyping Techniques</subject><subject>Humans</subject><subject>Immunization</subject><subject>Medical screening</subject><subject>Medicin och hälsovetenskap</subject><subject>Methylation</subject><subject>Molecular Medicine</subject><subject>Oncology</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomaviridae - isolation & purification</subject><subject>Papillomavirus Infections - diagnosis</subject><subject>Papillomavirus Infections - metabolism</subject><subject>Papillomavirus Vaccines - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Pregnancy</subject><subject>Quality assurance</subject><subject>Sensitivity and Specificity</subject><subject>Uterine Cervical Neoplasms - virology</subject><subject>Vaccination</subject><subject>Vaccination - statistics & numerical data</subject><subject>Viral Load</subject><issn>0007-0920</issn><issn>1532-1827</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNp9ks1uEzEUhUcIRNPCA7BBlti0iwH_TTxmUQmNkhSpUhaFteWx76RTJvZgT4ryHLwwniRtCVLZ2Ne-3zn-0cmydwR_JJiVnyInnExzTHGOZRrki2xCCkZzUlLxMptgjMWuc5KdxniXlhKX4nV2wmiBRVkUk-x3BeG-NbpD0QQA17rVZzS7WSzz2bxCvY_t0HqHet1DQL5Bwy2g2Sb4HrRDN960MGzH_cXWaTC-86vWoKXbVVt0PjpdIO3ssXAOFoLeOSdt5bt0kPH9KJhXF2-yV43uIrw9zGfZ9_nsW3WVXy8XX6sv17kpyumQlwUHK5gsiRYaU8O05E3R1FamQlhqGy4J4ZbUtcSy1sw2mFo-rTEzvKkNO8vyvW_8Bf2mVn1o1zpsldetOmz9SBUoLvBU0sTLZ_k-ePskehASzkrJuMRJe7nXJmAN1oAbgu6OLY46rr1VK3-vBGe8FCwZnB8Mgv-5gTiodRsNdJ124DdRUU6wwFIIktAP_6B3fhNc-spEiQKTIqXg_xRLFE1JShTZUyb4GAM0j1cmWI0hVPsQqhRCNUZNyaR5__dbHxUPqUsAPXxkarkVhKejn3f9A5VY6Gs</recordid><startdate>20200818</startdate><enddate>20200818</enddate><creator>Kyrgiou, Maria</creator><creator>Arbyn, Marc</creator><creator>Bergeron, Christine</creator><creator>Bosch, F. Xavier</creator><creator>Dillner, Joakim</creator><creator>Jit, Mark</creator><creator>Kim, Jane</creator><creator>Poljak, Mario</creator><creator>Nieminen, Pekka</creator><creator>Sasieni, Peter</creator><creator>Kesic, Vesna</creator><creator>Cuzick, Jack</creator><creator>Gultekin, Murat</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20200818</creationdate><title>Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)</title><author>Kyrgiou, Maria ; Arbyn, Marc ; Bergeron, Christine ; Bosch, F. Xavier ; Dillner, Joakim ; Jit, Mark ; Kim, Jane ; Poljak, Mario ; Nieminen, Pekka ; Sasieni, Peter ; Kesic, Vesna ; Cuzick, Jack ; Gultekin, Murat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-854ed73981a7a02c3a94f5fbd9a947d2df49114d1bb909ba3df02d46b03c4fbc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/700/1538</topic><topic>692/700/459/1748</topic><topic>706/648/160</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Cervix Uteri - virology</topic><topic>Colposcopy</topic><topic>Consensus</topic><topic>Consensus Statement</topic><topic>Cyclin-Dependent Kinase Inhibitor p16 - metabolism</topic><topic>Cytology</topic><topic>Drug Resistance</topic><topic>Early Detection of Cancer</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Genotyping</topic><topic>Genotyping Techniques</topic><topic>Humans</topic><topic>Immunization</topic><topic>Medical screening</topic><topic>Medicin och hälsovetenskap</topic><topic>Methylation</topic><topic>Molecular Medicine</topic><topic>Oncology</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomaviridae - isolation & purification</topic><topic>Papillomavirus Infections - diagnosis</topic><topic>Papillomavirus Infections - metabolism</topic><topic>Papillomavirus Vaccines - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Pregnancy</topic><topic>Quality assurance</topic><topic>Sensitivity and Specificity</topic><topic>Uterine Cervical Neoplasms - virology</topic><topic>Vaccination</topic><topic>Vaccination - statistics & numerical data</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kyrgiou, Maria</creatorcontrib><creatorcontrib>Arbyn, Marc</creatorcontrib><creatorcontrib>Bergeron, Christine</creatorcontrib><creatorcontrib>Bosch, F. Xavier</creatorcontrib><creatorcontrib>Dillner, Joakim</creatorcontrib><creatorcontrib>Jit, Mark</creatorcontrib><creatorcontrib>Kim, Jane</creatorcontrib><creatorcontrib>Poljak, Mario</creatorcontrib><creatorcontrib>Nieminen, Pekka</creatorcontrib><creatorcontrib>Sasieni, Peter</creatorcontrib><creatorcontrib>Kesic, Vesna</creatorcontrib><creatorcontrib>Cuzick, Jack</creatorcontrib><creatorcontrib>Gultekin, Murat</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kyrgiou, Maria</au><au>Arbyn, Marc</au><au>Bergeron, Christine</au><au>Bosch, F. Xavier</au><au>Dillner, Joakim</au><au>Jit, Mark</au><au>Kim, Jane</au><au>Poljak, Mario</au><au>Nieminen, Pekka</au><au>Sasieni, Peter</au><au>Kesic, Vesna</au><au>Cuzick, Jack</au><au>Gultekin, Murat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2020-08-18</date><risdate>2020</risdate><volume>123</volume><issue>4</issue><spage>510</spage><epage>517</epage><pages>510-517</pages><issn>0007-0920</issn><issn>1532-1827</issn><eissn>1532-1827</eissn><abstract>This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32507855</pmid><doi>10.1038/s41416-020-0920-9</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2020-08, Vol.123 (4), p.510-517 |
| issn | 0007-0920 1532-1827 1532-1827 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_470692 |
| source | MEDLINE; SWEPUB Freely available online; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | 692/700/1538 692/700/459/1748 706/648/160 Biomedical and Life Sciences Biomedicine Cancer Research Cellular biology Cervical cancer Cervix Uteri - virology Colposcopy Consensus Consensus Statement Cyclin-Dependent Kinase Inhibitor p16 - metabolism Cytology Drug Resistance Early Detection of Cancer Epidemiology Female Genotyping Genotyping Techniques Humans Immunization Medical screening Medicin och hälsovetenskap Methylation Molecular Medicine Oncology Papillomaviridae - genetics Papillomaviridae - isolation & purification Papillomavirus Infections - diagnosis Papillomavirus Infections - metabolism Papillomavirus Vaccines - therapeutic use Practice Guidelines as Topic Pregnancy Quality assurance Sensitivity and Specificity Uterine Cervical Neoplasms - virology Vaccination Vaccination - statistics & numerical data Viral Load |
| title | Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A16%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cervical%20screening:%20ESGO-EFC%20position%20paper%20of%20the%20European%20Society%20of%20Gynaecologic%20Oncology%20(ESGO)%20and%20the%20European%20Federation%20of%20Colposcopy%20(EFC)&rft.jtitle=British%20journal%20of%20cancer&rft.au=Kyrgiou,%20Maria&rft.date=2020-08-18&rft.volume=123&rft.issue=4&rft.spage=510&rft.epage=517&rft.pages=510-517&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-020-0920-9&rft_dat=%3Cproquest_swepu%3E2475015087%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2435012532&rft_id=info:pmid/32507855&rfr_iscdi=true |